Explore

Rapid Read Rapid Read
New Study Suggests Alzheimer's Memory Loss May Be Partially Reversible

New Study Suggests Alzheimer's Memory Loss May Be Partially Reversible

A recent study conducted by researchers at the Medical Faculty of the University Hospital Magdeburg has revealed that memory loss in Alzheimer's patients may not be solely due to the loss of nerve cells. The study, published in Nature Reviews Neurology, indicates that disruptions in brain network functions could also contribute to memory impairments. This finding suggests that some memory losses might be reversible if the brain's network functions are restored. The research highlights the potential for therapies that focus on enhancing brain network functions, such as targeted memory training and stimulation of brain areas, to improve memory performance in Alzheimer's patients.
PBS Newshour PBS Newshour
A look at 'super agers' and the science behind longer, sharper lives

A look at 'super agers' and the science behind longer, sharper lives

Experts explore the science behind "super agers" to uncover proven techniques for achieving longer, sharper lives.
Rapid Read Rapid Read
Experimental Drug Elraglusib Doubles One-Year Survival in Pancreatic Cancer

Experimental Drug Elraglusib Doubles One-Year Survival in Pancreatic Cancer

A new experimental drug, elraglusib, has shown to double the one-year survival rate for pancreatic cancer patients, according to a recent study published in Nature Medicine. The drug targets the protective web that pancreatic tumors build around themselves, enhancing the penetration of immune molecules and chemotherapy. In a trial involving 286 patients with advanced pancreatic cancer, those treated with elraglusib and chemotherapy had a median survival of 10.1 months, compared to 7.2 months for those receiving only chemotherapy. The study, led by Dr. Devalingam Mahalingam from Northwestern University Feinberg School of Medicine, highlights elraglusib's potential as a complement to existing therapies, such as immune checkpoint inhibitors and KRAS inhibitors.
Trendline Trendline
CONNECTA Therapeutics Advances Neuroplasticity Modulators for Fragile X Syndrome

CONNECTA Therapeutics Advances Neuroplasticity Modulators for Fragile X Syndrome

CONNECTA Therapeutics Advances Neuroplasticity Modulators for Fragile X Syndrome
Trendline Trendline
Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial

Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial

Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial
Trendline Trendline
Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study

Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study

Eli Lilly's Foundayo Shows Promising Results in Phase 3 Diabetes Study
Trendline Trendline
Doctors Discuss the Efficacy of Foods Mimicking GLP-1 Drugs and Their Impact on Appetite

Doctors Discuss the Efficacy of Foods Mimicking GLP-1 Drugs and Their Impact on Appetite

Doctors Discuss the Efficacy of Foods Mimicking GLP-1 Drugs and Their Impact on Appetite
Rapid Read Rapid Read
Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Ineffective and Risky

Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Ineffective and Risky

A recent review by the Cochrane Collaboration has concluded that anti-amyloid drugs, which target amyloid beta proteins in the brain, do not provide clinically meaningful benefits for patients with Alzheimer's disease. The review analyzed data from 17 clinical trials involving 20,342 participants with mild cognitive impairment or mild dementia due to Alzheimer's. Despite the removal of amyloid proteins from the brain, these drugs did not significantly impact cognitive decline or dementia severity. Furthermore, the review highlighted an increased risk of brain swelling and bleeding associated with these drugs, although most patients did not exhibit symptoms. The findings suggest that while these drugs can remove amyloid proteins, this does not translate into a meaningful clinical benefit for patients.
Trendline Trendline
Eli Lilly's Foundayo Shows Promising Diabetes Data, Easing FDA Safety Concerns

Eli Lilly's Foundayo Shows Promising Diabetes Data, Easing FDA Safety Concerns

Eli Lilly's Foundayo Shows Promising Diabetes Data, Easing FDA Safety Concerns
Rapid Read Rapid Read
Cochrane Review Finds Limited Efficacy in Alzheimer's Amyloid Drugs

Cochrane Review Finds Limited Efficacy in Alzheimer's Amyloid Drugs

A Cochrane Collaboration review has concluded that amyloid beta-targeting drugs for Alzheimer's disease show limited clinical efficacy. The analysis, which included data from 17 clinical trials involving 20,342 participants, found that these drugs have minimal impact on cognitive decline and dementia severity, while increasing the risk of brain bleeding and swelling. The review specifically examined Eisai/Biogen's Leqembi and Eli Lilly's Kisunla, among others. Despite some statistically significant results in early trials, the review emphasizes the lack of meaningful clinical benefits for patients. The findings have sparked debate among researchers, with some advocating for exploring alternative treatment mechanisms.
Trendline Trendline
Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes
Rapid Read Rapid Read
Cochrane Review Questions Efficacy of Anti-Amyloid Alzheimer's Drugs

Cochrane Review Questions Efficacy of Anti-Amyloid Alzheimer's Drugs

A recent analysis by the Cochrane health research organization has cast doubt on the efficacy of anti-amyloid drugs used in treating Alzheimer's disease. The review assessed 17 studies involving over 20,000 participants and concluded that these drugs, including Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, likely have no clinically meaningful positive effects on cognitive function or dementia severity. The analysis also noted a small increase in the risk of brain swelling associated with these medications. Despite some drugs like Leqembi and Kisunla receiving FDA approval based on statistically significant reductions in clinical decline, the review suggests that the overall impact of amyloid-targeting therapies is minimal.